START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center

/0 Comments/in /by

The START Center for Cancer Research (“START”), a global leader in early-phase oncology clinical trials, announces the expansion of its network with the acquisition of Carolina Urologic Research Center (“CURC”) the premier urologic clinical research site specializing in genitourinary (GU) oncology. This acquisition strengthens START’s capabilities in one of oncology’s fastest-growing disease areas. With an estimated 2.6 million new cases diagnosed each year, GU cancers now account for over 1 in 8 of all cancer diagnoses worldwide.

Click here to read entire article

Final Version: Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy

/0 Comments/in /by

 

Recent clinical trials have shown improvement in progression-free survival in men with metastatic prostate cancer (mPC) treated with combination poly-ADP ribose polymerase (PARP) inhibitors (PARPi) and novel hormonal therapy (NHT). Regulatory bodies in the USA, Canada, Europe, and Japan have recently approved this combination therapy for mPC. Common adverse events (AEs) include fatigue, nausea and vomiting, and anemia. Nuanced AE management guidance for these combinations is lacking. The panel objective was to develop expert consensus on AE management in patients with mPC treated with the combination PARPi + NHT.

Neal D. Shore, Michael S. Broder, Pedro C. Barata, Tony Crispino, André P. Fay, Jennifer Lloyd, Begoña Mellado, Nobuaki Matsubara, Nicklas Pfanzelter, Katrin Schlack, Paul Sieber, Andrey Soares, Hannah Dalglish, Alexander Niyazov, Saif Shaman, Michael A. Zielinski, Jane Chang, Neeraj Agarwal

Click here to read entire article

The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer

/0 Comments/in /by

The podcast moderator is Neal D Shore, MD who is joined by Michael S Cookson, MD & Eleni Efstathiou, MD

The goal of this podcast is to help doctors and patients learn about and discuss the different androgen deprivation therapy (ADT) options used to treat advanced prostate cancer. Advanced prostate cancer is a type of cancer that started in the prostate and has spread outside of the prostate. Prostate cancers generally need the male sex hormone, called testosterone, to grow. Treatment for advanced prostate cancer often includes lowering testosterone levels through medicines called ADTs. The authors discuss the HERO trial, which looked at relugolix (the only ADT taken orally [by mouth]) and compared it with another type of ADT called leuprolide, which is given by injection at a doctor’s office. The authors discuss the effectiveness and side effects of these.

Listen or read podcast transcript by clicking here

Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs

/0 Comments/in /by

From germline and somatic testing to androgen receptor pathway inhibitors (ARPIs), there have been a multitude of advancements in prostate cancer care. Here to break down the innovative diagnostics and treatments that are enhancing patient care is Dr. Neal Shore, Medical Director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina.

For a breakdown of the latest innovative diagnostics and treatments, click here & chose a media format (Audio, Podcast, Transcript, Transcript PDF)

Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer

/0 Comments/in /by

 

Siamak Daneshmand M.D., Ashish M. Kamat M.D., M.B., B.S., Neal D. Shore M.D., Joshua J. Meeks M.D., Ph.D., Matthew D. Galsky M.D., Joseph M. Jacob M.D., Michiel S. van der Heijden M.D., Ph.D., Stephen B. Williams M.D., M.B.A., M.S., Thomas Powles M.D., Sam S. Chang M.D., James W.F. Catto Ph.D., F.R.C.S. (Urol.), Sarah P. Psutka M.D., Félix Guerrero-Ramos M.D., Ph.D., Evanguelos Xylinas M.D., Makito Miyake M.D., Ph.D., Giuseppe Simone M.D., Ph.D., Karen Daniel Ph.D., Hussein Sweiti M.D., Christopher Cutie M.D., Andrea Necchi M.D.

Click here to read entire article

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

/0 Comments/in /by

Neal D. Shore, MD, Lead Investigator for the CREST trial.

Click here to read entire article

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now

/0 Comments/in /by

Authors: Neal Shore, MD , Sarah M. Nielsen, MS , Edward D. Esplin, MD, PhD, Emmanuel S. Antonarakis, MD, Pedro C. Barata, MD, Tomasz M. Beer, MD, Himisha Beltran, MD, Alan Bryce, MD, Michael S. Cookson, MD, E. David Crawford, MD, Tanya B. Dorff, MD, Daniel J. George, MD, Elisabeth I. Heath, MD, Brian T. Helfand, MD, PhD, Maha Hussain, MD, Rana R. Mckay, MD, Alicia K. Morgans, MD, MPH, Michael J. Morris, MD, Channing J. Paller, MD, Ashley E. Ross, MD, PhD, Oliver Sartor, MD, John Shen, MD, Paul Sieber, MD, Matthew R. Smith, MD, PhD, David R. Wise, MD, PhD, Andrew J. Armstrong, MD 

Click here to read entire article

In the Era of Treatment Intensification for Prostate Cancer, Why Are Some Living in the Past?

/0 Comments/in /by
Authors:

Jason R. Brown, MD, PhD (University Hospitals Seidman Cancer Center, Cleveland, Ohio / Case Comprehensive Cancer Center, Cleveland, Ohio)
Neal Shore, MD (Carolina Urologic Research Center, Myrtle Beach, South Carolina)
Pedro C. Barata, MD, MSc (University Hospitals Seidman Cancer Center, Cleveland, Ohio / Case Comprehensive Cancer Center, Cleveland, Ohio)
 

Click here to read entire article

Editorial Comment: Integrating Broad Panel Somatic and Germline Testing in Prostate Cancer Care

/0 Comments/in /by

Author Neal Shore, MD, FACS, Carolina Urologic Research Center, AUC Urology Specialists, 823 82nd Parkway, Myrtle Beach, SC , 29572

Click here to read entire article

Evaluating the Importance of Practice-level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology

/0 Comments/in /by

Authors: Neal Shore ∙ Gordon Brown ∙ Benjamin Lowentritt ∙ Lorraine O’Donnell ∙ Wanda Wilt ∙ Sabree Burbage ∙ Ibrahim Khilfeh  ∙ Franklin Gaylis

Click here to read entire article